Assessment of Effect of Saroglitazar in Patients with Diabetic Dyslipidemia with Very High Triglycerides Level

Saroglitazar in Patients with Diabetic Dyslipidemia with Very High Triglycerides Level

Abstract

Background: The aim is to assess effect of Saroglitazar in patients with diabetic dyslipidemia. Subjects and Methods: Eighty- six type II DM patients of either gender were enrolled and parameters such as serum creatinine, S.G.O.T, S.G.P.T and lipid profile were determined. Patients were prescribed 4 mg Saroglitazar once daily and patients were recalled regularly. All variables were recorded at baseline, 12 weeks and 36 weeks. Results: Out of 86 patients, males were 56 and females were 30. The mean weight was 64.2 3.7Kgs, height was 171.2 14.2 cms and BMI was 26.2 5.9 Kg/m². The mean total cholesterol level at baseline, 12 weeks and 36 weeks found to be 324.5, 232.6 and 168.4, triglyceride level was 542.3, 342.5 and 290.5, LDL-C was 167.3, 114.2 and 105.2, HDL-C was 41.2, 43.2 and 43.6, SGPT was 34.6, 38.2 and 37.2, SGOT was 45.3, 42.6 and 40.3 and creatinine level was 0.6, 0.6 and 0.5 respectively. The difference was significant (P< 0.05). Conclusion: Saroglitazar found to be efficient in diabetic dyslipidemia with very high triglycerides level.